EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
TARRYTOWN, N.Y., Oct. 17, 2014 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net)... Biopharmaceuticals, OphthalmologyRegeneron Pharmaceuticals, EYLEA, aflibercept, Diabetic Macular Edema (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2014 Category: Pharmaceuticals Source Type: news
Regeneron's Eylea works better vs Avastin and Lucentis in study
(Reuters) - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis. (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
FDA grants Priority Review for Lucentis in diabetic retinopathy
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted to file the company's supplemental Biologics License Application (sBLA) and granted Priority Review of Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy, an eye disease that impacts nearly 7.7 million Americans. The FDA confirmed action date is February 6, 2015. (Source: Roche Investor Update)
Source: Roche Investor Update - October 8, 2014 Category: Pharmaceuticals Source Type: news
Limit Ranibizumab Injections in Macular DegenerationLimit Ranibizumab Injections in Macular Degeneration
Investigators have identified an optimum number of injections of the vascular endothelial growth factor inhibitor for wet age-related macular degeneration in the first year of treatment. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Risk Factors for Geographic Atrophy in the CATT TrialRisk Factors for Geographic Atrophy in the CATT Trial
The CATT results are discussed -- will they help ophthalmologists choose either bevacizumab or ranibizumab? Medscape Ophthalmology (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - September 19, 2014 Category: Opthalmology Tags: Ophthalmology Viewpoint Source Type: news
Cheaper alternative to licensed drug for treating eye disease has similar side-effects
(Wiley) Health policies which favour using ranibizumab for treating eye disease in older people over safety concerns for a cheaper alternative should take account of a new Cochrane Review published today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 14, 2014 Category: Global & Universal Source Type: news
Prompt or Delayed Laser Equal in Diabetic Macular EdemaPrompt or Delayed Laser Equal in Diabetic Macular Edema
For patients receiving intravitreal ranibizumab, the timing of laser treatment for diabetic macular edema has little effect on outcome, report researchers. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 14, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Ranibizumab vs Laser in Diabetic Macular EdemaRanibizumab vs Laser in Diabetic Macular Edema
Are the differences significant enough to subject patients to the high injection burden required for anti-VEGF treatment? Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 6, 2014 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news
More Safety Data Needed for Intravitreal Anti-VEGF AgentsMore Safety Data Needed for Intravitreal Anti-VEGF Agents
Intravitreal use of bevacizumab and ranibizumab does not appear to cause major cardiovascular events or non-ocular bleeding in patients with eye disease, according to a meta-analysis from France. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 5, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Anti-VEGF Improves Quality of Life in Macular DegenerationAnti-VEGF Improves Quality of Life in Macular Degeneration
When patients' vision improved when receiving ranibizumab, their quality of life improved too. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 7, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
France to back Roche cancer drug as cheaper eye treatment
PARIS (Reuters) - The French government, looking to cut healthcare costs, plans to authorize the use of Roche cancer drug Avastin as an alternative eye disease treatment to the much pricier Lucentis, marketed by both Roche and Novartis. (Source: Reuters: Health)
Source: Reuters: Health - July 2, 2014 Category: Consumer Health News Tags: healthNews Source Type: news
Switch From Lucentis to Avastin Could Save Medicare $18BSwitch From Lucentis to Avastin Could Save Medicare $18B
Medicare could slash $18 billion in spending over the course of 10 years if physicians treated patients with vision-robbing ailments with bevacizumab instead of ranibizumab. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 17, 2014 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Wet AMD drug changed by Italy government
Dr Steven Bradshaw, a drug policy expert and former ophthalmologist, is disappointed at the news of the Italian government’s decision to substitute wet age-related macular degeneration treatment drug, from Lucentis to Roche’s Avastin. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 16, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: Industry News avastin italy Latest News lucentis Steven Bradshaw wet age-related macular degeneration Source Type: news
Study Finds Selecting Cheaper Eye Drug Could Save U.S. Billions
Researchers at the University of Michigan have found that if eye doctors began to prescribe a less expensive eye drug for the wet form of macular degeneration or those who have diabetic macular edema, the U.S. Medicare system could save as much as $18 billion over 10 years. Patients suffering from these two conditions currently have two treatment options: bevacizumab (branded as Avastin), which costs $55 per treatment, or ranibizumab (branded as Lucentis) which costs $2,023 per treatment. Ranibizumab is almost 40 times more expensive than bevacizumab, and the researchers found that the drugs are very similar in terms of ef...
Source: Pharmaceutical Online News - June 9, 2014 Category: Pharmaceuticals Source Type: news
